Tags

Type your tag names separated by a space and hit enter

Increased visfatin concentrations in women with gestational diabetes mellitus.
Clin Sci (Lond). 2006 May; 110(5):605-9.CS

Abstract

The recently discovered adipocytokine visfatin has insulin-like properties. It lowers blood glucose and improves insulin sensitivity; however, clinical data on visfatin are limited. To evaluate the role of visfatin in GDM (gestational diabetes mellitus), we determined visfatin levels in women with GDM and in healthy pregnant controls. Furthermore, visfatin concentrations were investigated longitudinally during pregnancy and after delivery in a subgroup of women with GDM. Blood for measurement of visfatin and metabolic parameters was obtained from 64 women with GDM [median week of gestation, 34 (interquartile range, 27-36) weeks] and 30 healthy pregnant controls [median week of gestation, 34 (interquartile range, 28-36) weeks]. In a subgroup of 24 women with GDM, visfatin, leptin and metabolic parameters were investigated twice during pregnancy (28-30 and 38-40 weeks of gestation) and 2 weeks after delivery. In the cross-sectional analysis, median visfatin levels were significantly elevated in women with GDM [64.0 (interquartile range, 50.9-74.8) ng/ml] compared with controls [46.0 (interquartile range, 36.9-54.6) ng/ml; P<0.0001]. In women with GDM, visfatin correlated with week of gestation at the time of blood draw (R=0.35, P=0.005). No association with fasting glucose, insulin, homoeostasis model assessment-insulin resistance or body mass index was observed. According to the longitudinal analysis, visfatin increased during pregnancy (P=0.002) and rose further after delivery (P=0.014), whereas leptin and insulin levels decreased after parturition (both P<0.001). In conclusion, visfatin is elevated in women with GDM and increases during the course of pregnancy as well as after delivery. Furthermore, visfatin shows no association with insulin and leptin in women with GDM.

Authors+Show Affiliations

Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria. katarzyna.krzyzanowska@wienkav.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16489932

Citation

Krzyzanowska, Katarzyna, et al. "Increased Visfatin Concentrations in Women With Gestational Diabetes Mellitus." Clinical Science (London, England : 1979), vol. 110, no. 5, 2006, pp. 605-9.
Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci. 2006;110(5):605-9.
Krzyzanowska, K., Krugluger, W., Mittermayer, F., Rahman, R., Haider, D., Shnawa, N., & Schernthaner, G. (2006). Increased visfatin concentrations in women with gestational diabetes mellitus. Clinical Science (London, England : 1979), 110(5), 605-9.
Krzyzanowska K, et al. Increased Visfatin Concentrations in Women With Gestational Diabetes Mellitus. Clin Sci. 2006;110(5):605-9. PubMed PMID: 16489932.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased visfatin concentrations in women with gestational diabetes mellitus. AU - Krzyzanowska,Katarzyna, AU - Krugluger,Walter, AU - Mittermayer,Friedrich, AU - Rahman,Rupa, AU - Haider,Dominik, AU - Shnawa,Nadja, AU - Schernthaner,Guntram, PY - 2006/2/24/pubmed PY - 2006/6/30/medline PY - 2006/2/24/entrez SP - 605 EP - 9 JF - Clinical science (London, England : 1979) JO - Clin. Sci. VL - 110 IS - 5 N2 - The recently discovered adipocytokine visfatin has insulin-like properties. It lowers blood glucose and improves insulin sensitivity; however, clinical data on visfatin are limited. To evaluate the role of visfatin in GDM (gestational diabetes mellitus), we determined visfatin levels in women with GDM and in healthy pregnant controls. Furthermore, visfatin concentrations were investigated longitudinally during pregnancy and after delivery in a subgroup of women with GDM. Blood for measurement of visfatin and metabolic parameters was obtained from 64 women with GDM [median week of gestation, 34 (interquartile range, 27-36) weeks] and 30 healthy pregnant controls [median week of gestation, 34 (interquartile range, 28-36) weeks]. In a subgroup of 24 women with GDM, visfatin, leptin and metabolic parameters were investigated twice during pregnancy (28-30 and 38-40 weeks of gestation) and 2 weeks after delivery. In the cross-sectional analysis, median visfatin levels were significantly elevated in women with GDM [64.0 (interquartile range, 50.9-74.8) ng/ml] compared with controls [46.0 (interquartile range, 36.9-54.6) ng/ml; P<0.0001]. In women with GDM, visfatin correlated with week of gestation at the time of blood draw (R=0.35, P=0.005). No association with fasting glucose, insulin, homoeostasis model assessment-insulin resistance or body mass index was observed. According to the longitudinal analysis, visfatin increased during pregnancy (P=0.002) and rose further after delivery (P=0.014), whereas leptin and insulin levels decreased after parturition (both P<0.001). In conclusion, visfatin is elevated in women with GDM and increases during the course of pregnancy as well as after delivery. Furthermore, visfatin shows no association with insulin and leptin in women with GDM. SN - 0143-5221 UR - https://www.unboundmedicine.com/medline/citation/16489932/Increased_visfatin_concentrations_in_women_with_gestational_diabetes_mellitus_ L2 - https://portlandpress.com/clinsci/article-lookup/doi/10.1042/CS20050363 DB - PRIME DP - Unbound Medicine ER -